TERLIVAZ
Peakterlipressin
NDAINTRAVENOUSPOWDERPriority Review
Approved
Sep 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Mechanism of Action
Vasopressin Receptor Agonists
Pharmacologic Class:
Vasopressin Receptor Agonist
Clinical Trials (2)
Follow-up of Glypressin (Terlipressin) Clinical Efficacy in the Treatment of Bleeding Oesophageal Varices
Started Nov 2010
20 enrolled
Gastrointestinal BleedingOesophageal Varices
A Study of Terlipressin in Patients With Hepatorenal Syndrome Type 1
Started Nov 2007
8 enrolled
Hepatorenal Syndrome Type 1
Loss of Exclusivity
LOE Date
Apr 5, 2037
134 months away
Patent Expiry
Apr 5, 2037
Exclusivity Expiry
Sep 14, 2029
Patent Records (1)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 10335452 | Apr 5, 2037 | U-3711 |